We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience. You can read our Cookie Policy here.


Galapagos Delivers Third Candidate Drug in GSK Alliance, Receives €5.7 Million

Want a FREE PDF version of This News Story?

Complete the form below and we will email you a PDF version of "Galapagos Delivers Third Candidate Drug in GSK Alliance, Receives €5.7 Million"

Technology Networks Ltd. needs the contact information you provide to us to contact you about our products and services. You may unsubscribe from these communications at any time. For information on how to unsubscribe, as well as our privacy practices and commitment to protecting your privacy, check out our Privacy Policy

Read time:
Galapagos NV has announced that it has successfully identified a third candidate drug in its arthritis alliance with GlaxoSmithKline (GSK). Galapagos also reached milestones for other compounds in the alliance. Together, these milestones trigger cash payments totaling €5.7 million to Galapagos.

This latest pre-clinical candidate is a small molecule that meets all the chemical and biological criteria set by GSK for a potential new medicine. Galapagos developed the candidate against a novel drug target from its proprietary platform. Galapagos will now start scale-up chemistry and comprehensive safety evaluation, with the aim to initiate Phase I clinical trials early 2011.

"We are proud to deliver the third candidate drug in the arthritis alliance with GSK," said Onno van de Stolpe, Chief Executive Officer of Galapagos. "Multiple candidates provide more shots on goal in terms of getting a drug to the market. It is gratifying that our discovery organization has been so successful in this alliance."